查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1146280

馬來西亞糖尿病治療設備市場 - 增長、趨勢、COVID-19 的影響和預測 (2022-2027)

Malaysia Diabetes Care Devices Market - Growth, Trends, and Forecasts (2022 - 2027)
出版日期: | 出版商: Mordor Intelligence | 英文 70 Pages | 商品交期: 2-3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

在 2022 年至 2027 年的預測期內，馬來西亞的糖尿病治療設備市場預計將以超過 5.1% 的複合年增長率增長。

馬來西亞衛生部表示，這個東南亞國家在 24 小時內記錄了 5,809 例新的 COVID-19 病例，其中 5,782 例是國內感染，27 例是進口感染，使全國總數達到 2,541,147 例。宣布這是到目前為止，大約 78.4% 的馬來西亞人已經接種了至少一劑針對 COVID-19 的疫苗，而 75.9% 的人已完全接種疫苗。衛生部告訴《星期日星報》，今年馬來西亞 10 例 COVID-19 死亡病例中約有 4 例患有糖尿病。在馬來西亞，五分之一的人患有糖尿病，約有 390 萬 18 歲及以上的人患有糖尿病。

年輕糖尿病患者的數量正在增加。越來越多的年輕人患上糖尿病，在過去 15 年中，18 至 40 歲的人數翻了一番。越來越多的糖尿病患者意味著疾病及其並發症的負擔越來越重，例如心髒病、中風、失明、慢性腎病和下肢截肢。

其實，大馬死於新冠肺炎的，大部分都患有糖尿病、高血壓等基礎疾病，而且數字很高。

主要市場趨勢

在馬來西亞糖尿病治療器械市場，管理器械佔有較高的市場份額

馬來西亞是西太平洋地區糖尿病患病率最高的國家，也是世界上糖尿病患病率最高的國家之一，每年的醫療保健費用約為 6 億美元。這種上升趨勢是由多種因素造成的，包括人口增長、人口老齡化、城市化以及肥胖率和缺乏運動率的上升。本研究的目的是系統地掌握馬來西亞糖尿病和糖尿病前期的患病率，明確其特徵，並進行估計。胰島素泵的使用在西方急劇增加，尤其是在 1 型糖尿病患者中，但它在馬來西亞的使用仍然非常有限。基礎胰島素注射取代了中效和長效皮下胰島素注射，以預設的速率全天持續提供胰島素，該速率可根據個人的具體要求進行修改。

這是一項由阿斯利康與馬來西亞內分泌和代謝學會 (MEMS) 合作支持的社區倡議，這項初步調查將於 2021 年 4 月 12 日至 5 月 9 日在多家藥房和媒體合作夥伴的支持下進行。在線日期。這項初步調查的目的是獲得馬來西亞意識水平的基線，並確定關鍵的知識差距。從今年的 2,539 份回復中得出的見解將決定阿斯利康和 MEMS 在來年如何塑造他們的公共教育工作。

政府在預測期內推動市場的舉措。

馬來西亞糖尿病患者人數上升

由於糖尿病和糖尿病前期在馬來西亞呈上升趨勢，馬來西亞政府實施了一項全國性的糖尿病預防和控制計劃。馬來西亞政府應制定全面的方法和計劃來提高糖尿病知識、控制、預防和治療，以降低該國的糖尿病患病率。最近的一項 NHMS 發現，馬來西亞有二分之一的成年人超重或肥胖。糖尿病患者血液中的葡萄糖和糖含量很高。糖尿病是一種當身體不能產生足夠的激素胰島素來控制血糖水平時發生的疾病。當身體不能有效使用胰島素時，也可能發生這種情況，也稱為胰島素抵抗。推動這一過程的因素包括肥胖、不健康的飲食習慣、久坐的生活方式和遺傳。在馬來西亞，該部國家糖尿病登記處（NDR）的統計數據顯示，84% 的糖尿病患者超重，其中大多數是 18 至 40 歲的年輕馬來西亞人。該部目前正在考慮一項名為“Sama-Sama 計劃”的倡議。它旨在幫助糖尿病患者的家人和護理人員提供支持並改善糖尿病控制和預後。 “在這個項目中，該部正在與私營部門合作培訓醫療保健提供者和護理人員。在這個項目中，該部與私營公司合作培養衛生工作者，從而培養護理人員，以增強和提供支持，以改善疾病控制和結果.

因此，馬來西亞的糖尿病治療設備市場預計將在未來幾年逐漸擴大。

競爭格局

連續血糖監測等糖尿病護理設備中的新技術擴大了監測設備的市場。參與者之間的併購，例如 Dexcom 收購 TypeZero Technologies，正在為胰島素自動給藥舖平道路。通過此次收購，Dexcom 不僅將推動血糖連續監測設備市場的發展，還將引領人工胰腺系統的研發競賽。

其他好處

  • Excel 格式的市場預測 (ME) 表
  • 三個月的分析師支持

內容

第一章介紹

  • 研究假設和市場定義
  • 調查範圍

第二章研究方法論

第 3 章執行摘要

第四章市場動態

  • 市場概覽
  • 市場驅動因素
  • 市場製約因素
  • 產業吸引力 - 波特五力分析
    • 新進入者的威脅
    • 買方/消費者議價能力
    • 供應商的議價能力
    • 替代品的威脅
    • 競爭公司之間的敵對關係

第 5 章市場細分

  • 監控設備
    • 自我血糖監測設備（價值和數量，2016-2027 年）
      • 血糖儀設備
      • 試紙
      • 柳葉刀
    • 連續血糖監測（價值和數量，2016-2027 年）
      • 傳感器
      • 耐用品
  • 託管設備
    • 胰島素泵（價值和數量，2016-2027 年）
      • 胰島素泵裝置
      • 胰島素泵儲液器
      • 輸液器
    • 胰島素注射器（價值和數量，2016-2027 年）
    • 胰島素藥筒（價值和數量，2016-2027 年）
    • 一次性筆（價格和數量，2016-2027 年）

第六章市場指標

  • 1 型糖尿病人口（2016-2027 年）
  • 2 型糖尿病人口（2016-2027 年）

第七章競爭格局

  • 公司簡介
    • Becton and Dickenson
    • Medtronic
    • Insulet
    • Tandem
    • Ypsomed
    • Novo Nordisk
    • Sanofi
    • Eli Lilly
    • Abbottt
    • Roche
    • Lifescan（Johnson &Johnson）
    • Dexcom
  • 企業佔有率分析

第8章 市場機會與未來趨勢

簡介目錄
Product Code: 91784

The Malaysia Diabetes Care Devices Market is expected to register a CAGR greater than 5.1% over the forecast period, 2022-2027.

The Malaysian Ministry of Health announced that the Southeast Asian nation recorded 5,809 new COVID-19 cases in 24 hours, including 5,782 domestically infected and 27 imported ones, bringing the national tally to 2,541,147. So far, about 78.4 percent of the Malaysian population have received at least one dose of vaccine against COVID-19, while 75.9 percent have been fully vaccinated. Out of every 10 people who died from COVID-19 in Malaysia this year, about four of them had diabetes, the Health Ministry tells Sunday Star. In Malaysia, one in five people lives with diabetes which works out to about 3.9 million people aged 18 and above.

Young diabetics are on the rise. A higher number of younger people are getting diabetes, with the number of patients aged between 18 and 40 doubling over the past 15 years. The rising number of diabetics means an increased burden of the disease and its complications: heart disease, stroke, blindness, chronic kidney disease, and lower limb amputation, among others.

In fact, most of the coronavirus deaths in Malaysia have underlying comorbidities, with diabetes and hypertension topping the list.

Key Market Trends

Management Devices Hold Highest Market Share in Malaysia Diabetes Care Devices Market

Malaysia has the highest rate of diabetes in the Western Pacific region and one of the highest in the world and costing around 600 million US dollars per year. The rising trend is due to several factors, including population growth, population aging, urbanization, and rising obesity and physical inactivity rates. The rising incidence of diabetes and its consequences in Malaysia inspired this study to systematically identify, characterize, and estimate the pooled prevalence of diabetes and prediabetes in Malaysia. Although the use of insulin pumps in the West has increased by leaps and bounds, especially among type 1 diabetic individuals, its use in Malaysia remains very limited. The basal insulin infusion, which substitutes the intermediate- or long-acting subcutaneous insulin injection, provides insulin continuously throughout the day at pre-set rates that are changed based on the individual's specific requirements.

A community initiative supported by AstraZeneca in partnership with the Malaysian Endocrine & Metabolic Society (MEMS), The first-ever survey took place online from 12 April until 9 May 2021, with the support of several pharmacies and media partners. The purpose of this inaugural survey is to obtain a baseline of Malaysia's awareness level and also to identify key knowledge gaps. The insights from this year's 2,539 responses (which have been stratified to represent the overall population) will shape the way AstraZeneca and MEMS conceptualises public education initiatives in the year ahead.

The Goverenment intiatives driving the market in forecast period.

Increasing Diabetes Population in Malaysia

Because diabetes and prediabetes are on the rise in Malaysia, the Malaysian government implements diabetes prevention and control programs across the country. The Malaysian government should establish a comprehensive approach and plan to improve diabetes knowledge, control, prevention, and treatment to reduce the prevalence of diabetes in the country. Being overweight and obese are key drivers of the younger diabetes population in Malaysia. recent NHMS found that one in two adults in Malaysia is overweight or obese. Those with diabetes have high levels of glucose or sugar in their blood. It's a disease that is caused by the body not producing enough of the hormone insulin to control the amount of blood sugar. It can also be caused when the body doesn't use insulin efficiently, also known as insulin resistance. Factors that drive this process include obesity, unhealthy eating habits, sedentary lifestyles, and genetics. In Malaysia, current statistics from the ministry's National Diabetes Registry (NDR)show that 84% of patients with diabetes are overweight, and among them are young Malaysians aged 18 to 40. The ministry is currently looking into an initiative known as the Sama-Sama program, which aims to empower family members and caregivers to provide support for people living with diabetes to improve control and outcomes of the disease. "Under the program, the ministry is joining forces with the private sector to train healthcare providers and later, caregivers. The ministry is now investigating the Sama-Sama program, which aims to empower family members and caregivers to offer support for persons living with diabetes to enhance disease control and outcomes. The ministry is collaborating with the commercial sector on the program to train healthcare personnel and, subsequently, carers.

As a result, the diabetes care devices market in Malaysia is predicted to expand gradually in the coming years.

Competitive Landscape

The new technologies in diabetes devices, like continuous glucose monitoring, increased the market for monitoring devices. The mergers and acquisitions between the players, like the acquisition of TypeZero Technologies by Dexcom, are paving the way for automated insulin delivery. The acquisition has sent Dexcom ahead on its way in the race to create an artificial pancreas system, rather than merely offering a boost to the continuous glucose monitoring devices market.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
  • 4.3 Market Restraints
  • 4.4 Industry Attractiveness - Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 Monitoring Devices
    • 5.1.1 Self-monitoring Blood Glucose Devices (Value and Volume, 2016 - 2027)
      • 5.1.1.1 Glucometer Devices
      • 5.1.1.2 Test Strips
      • 5.1.1.3 Lancets
    • 5.1.2 Continuous Blood Glucose Monitoring (Value and Volume, 2016 - 2027)
      • 5.1.2.1 Sensors
      • 5.1.2.2 Durables
  • 5.2 Management Devices
    • 5.2.1 Insulin Pump (Value and Volume, 2016 - 2027)
      • 5.2.1.1 Insulin Pump Device
      • 5.2.1.2 Insulin Pump Reservoir
      • 5.2.1.3 Infusion Set
    • 5.2.2 Insulin Syringes (Value and Volume, 2016 - 2027)
    • 5.2.3 Insulin Cartridges (Value and Volume, 2016 - 2027)
    • 5.2.4 Disposable Pens (Value and Volume, 2016 - 2027)

6 MARKET INDICATORS

  • 6.1 Type-1 Diabetes population (2016-2027)
  • 6.2 Type-2 Diabetes population (2016-2027)

7 COMPETITIVE LANDSCAPE

  • 7.1 Company Profiles
    • 7.1.1 Becton and Dickenson
    • 7.1.2 Medtronic
    • 7.1.3 Insulet
    • 7.1.4 Tandem
    • 7.1.5 Ypsomed
    • 7.1.6 Novo Nordisk
    • 7.1.7 Sanofi
    • 7.1.8 Eli Lilly
    • 7.1.9 Abbottt
    • 7.1.10 Roche
    • 7.1.11 Lifescan (Johnson &Johnson)
    • 7.1.12 Dexcom
  • 7.2 Company Share Analysis

8 MARKET OPPORTUNITIES AND FUTURE TRENDS